|
TARS | Tarsus Pharmaceuticals, Inc. |
|
|
TARS | Tarsus Pharmaceuticals, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.13 |
| Leverage | 37.32% |
| Market Cap | $ 2.7B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -81.0m |
| Margin | -22.23% |
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.